The c-Mpl receptor for thrombopoietin and its recombinant related protein, the megakaryocyte growth and development factor (MGDF), is also expressed on circulating platelets. In the present study we evaluated the effect of MGDF on platelet aggregation in platelet-rich plasma (PRP) and in whole blood. The results obtained indicate that MGDF by itself did not affect platelet aggregation. However, when added before other agonists such as adenosine diphosphates (ADP), epinephrine (EPI), and thrombin (THR), it rendered platelets more sensitive. This "priming" effect of MGDF was dependent on the dose and on the time of platelet preincubation, and it occurred both in PRP and in wholeblood platelet aggregation. MGDF also "primed the release HYSIOLOGIC PRODUCTION of platelets is thought to require at least two humoral growth factors that regulate proliferation and maturation of megakaryocytes.' One is a megakaryocyte colony-stimulating factor (meg-CSF), which induces the proliferation and differentiation of megakaryocyte progenitors.',2 The second is thrombopoietin, a novel megakaryocyte growth and development factor, which promotes the maturation of megakaryocyte^.^.^ It has been suggested that meg-CSF and thrombopoietin regulate megakaryocyte maturation by binding to the c-Mpl, a member of the hematopoietic receptor family encoded by the protooncogene c-mpl."' After cloning of human and murine complementary DNA for thrombopoietin,""'4 several groups have investigated in vitro and in vivo the biologic properties of the recombinant megakaryocyte growth and development factor (MGDF), a protein related to thrombopoietin. The MGDF has been shown to bind the c-Mpl re~eptor'""~ and to stimulate platelet production when injected in mice'""3 and in nonhuman primates.I5
of adenosine triphosphates and the production of thromboxane B, by platelets stimulated with ADP, EPI, and THR. When added 15 seconds after the preincubation of platelets with subthreshold concentrations of ADP, EPI, and THR, MGDF exhibited a synergism with these agonists. Moreover, we observed a "priming" effect of MGDF on the phosphorylation of p-42 mitogen-activated protein kinase promoted by ADP, EPI, and THR. These observations suggest that thrombopoietin may play a physiologic role in modulating the response of platelets to several stimuli and thereby their hemostatic potential.
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tors were expressed on human platelets.(' .' (' Therefore, in light of the potential clinical use of the MGDF, the question of whether it may affect platelet functions arises."
In the present study we evaluated the effect of MGDF on platelet aggregation in platelet-rich plasma (PRP) and in whole blood. The results obtained indicate that platelet activation in response to certain agonists was enhanced on exposure to MGDF. This observation suggests that thrombopoietin serves a spectrum of functions beyond the maturation of megakaryocytic lineage, including modulation of hemostatic properties of platelets.
MATERIALS AND METHODS

Reagents. Recombinant human MGDF was a gift of
Dr J.L. Nichol (Amgen Inc, Thousand Oaks, CA). Adenosine diphosphates (ADP) and bovine thrombin (THR) were obtained from Sigma Chemical CO (St Louis. MO). Epinephrine (EPI) was obtained from Helena Laboratories (Beaumont, TX). Luciferin and luciferase were purchased from Mascia Brunelli (Milano, Italy). The ELISA kit for thromboxane Bz (TXB2) determination was purchased from Biotrac (Amersham International, Amersham, UK). Polyclonal and monoclonal anti-p42""'k antibodies and antiphosphotyrosine monoclonal antibody were from Affinity Research Products Ltd (Nottingham, UK).
Plateletpreparation und aggregation studies. Venous blood was obtained by venipuncture from healthy adult donors (age range, 24 to 30) that had not taken any medications for at least 2 weeks. Nine volumes of blood were withdrawn in 1 v01 of 3.8% trisodium citrate. PRP was prepared by centrifugation for 15 minutes at 18Og. Plateletpoor plasma (PPP) was obtained by centrifugation at 2,000g for 10 minutes.I8 Platelet aggregation in PRP was performed as previously described,Ix according to Born's method, at 37°C with constant rate of stimng at 1,000 rpm in the lumi-aggregometer (Chronolog, Havertown, PA) using PPP as reference. The maximal aggregation was quantified according to the Weiss formula."
Platelet aggregation in whole blood was assessed in whole-blood lumi-aggregometer (Chronolog) by recording the increase in electrical impedance in I -m L sample of blood diluted onefold with Tyrode's buffer containing 2 U/mL of heparin and stirred at 1,000 rpm at 37"C.z" The system was calibrated so that a 5-ohm change in impedance corresponded to a 20-mm deflection of the pen. Aggregation was quantified as ( I ) the surface area under the curve relating electric impedance to time (ohms per seconds), (2) maximum amplitude (ohms). and (3) maximum rate of increase (ohms per seconds) PRP or whole-blood samples were preincubated with MGDF (0.25 to 120 ng/mL) directly in the lumi-aggregometer for variable periods of time at 37°C. before a second agonist was added. The following agonists were used: ADP (0.1 to IO pmol/L), EPI (0.8 to 24 pmoll L), and THR (0.02 to 1.2 UlmL). The "priming" index (PI) was calculated according to Gay'* as the response to MGDF and agonists together divided by the sum of the individual stimulus response. By this calculation a PI > I .0 indicated synergism, a PI = 1 indicated additive response, and PT < I indicated inhibition.22 Moreover, the synergic effect of MGDF on ADP, EPI, and THR was evaluated by using subthreshold concentrations of these aggregating agents followed, 15 seconds later, by the addition of MGDF.
When platelet aggregation in PRP and whole blood were measured repeatedly the variation versus the previous measurement was, respectively, within 5% and 8%.
In selected experiments luciferin-luciferase reagent was added to PRP 60 seconds before the addition of aggregating agents." Luminescence caused by the release of adenosine triphosphates (ATP) during aggregation was compared with the luminescence induced by 2 nmol of ATP standard as described by Feinman et al. '3 Measurement ofthromhoxane B? (TXB?) production. The generation of TXBz by stimulated platelets in PRP was evaluated as previously described.2J Briefly, at the indicated time after the addition of agonists the reaction was stopped by addition of 5 pmol/L indomethacin, platelets were centrifuged at 12,000g for 2 minutes, and plasma was removed and stored at -60°C. After appropriate dilution TXBz levels were determined by ELISA.
Western blot analvsis and immunoprecipitation studies. Platelets (4 X IOx/ mL) were incubated at 37°C for 5 minutes with or without ADP (0.5 pmol/L), EPI (2 pmol/L), or THR (0.6 UlmL) in the presence or absence of MGDF (40 ng/mL). At the end of incubation, platelets were extracted with cold DIM buffer (50 mmol/L PIPES pH 6.8, 1 0 0 mmol/L NaCI, 5 mmol/L MgCL, 300 mmol/L sucrose, 5 mmol/L EGTA, 2 mmol/L orthovanadate) containing 1% Triton X-100 (Sigma Chemical CO) and a mixture of proteinase inhibitors (I mmolL phenylmethylsulfonylfluoride, IO pg/mL leupeptin, 0.15 U/mL aprotinin, I pglmL pepstatin A) for 20 minutes at 4°C. and centrifuged at I5,OOOg for 20 minutes. The protein concentration of platelet lysates was determined according to Bradford's technique" and the protein content of the samples was normalized by appropriate dilution with cold DIM buffer. The supernatant was precleaned for I hour with 50 pL of Sepharose protein A (Sigma Chemical CO) (3 mg/sample). The samples (50 pg) were then absorbed by antisera coupled to Sepharose protein A. Bound proteins were repeatedly washed in DIM buffer and eluted in boiling Laemmli buffer. Thirtymicroliter samples of eluted proteins were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose. The filters were incubated for 1 hour with a blocking solution containing 10% low-fat milk in 20 mmol/L Tris-HCI pH 7.6 and 17 mmol/L NaCI. Antisera were then added at the same solution, and the incubation was carried out for 2 hours at room temperature. For detection the filters were washed three times with phosphate-buffered saline (PBS) containing 0.05% Tween 20 and reacted for I hour at room temperature with horseradish peroxidase-conjugated protein A. After washing the filters were reacted for 1 minute with chemiluminescence reagent (ECL; Sigma) and exposed to an autoradiography film for 1 to 15 minutes. minutes before ADP, EPI, or THR, MGDF enhanced in a dose-dependent manner the platelet aggregation (Fig 1 A) . As shown in Fig IB the minimal "priming" dose of MGDF, added 5 minutes before the agonists, was 0.25 ng/mL for the stimulation with EPI and 0.5 ng/mL for stimulation with ADP and THR. The "priming" effect reached a plateau at 40 ng/mL. However, the preincubation time also affected the response of platelets to MGDF (Figs 2 and 3) . When low concentrations of MGDF were used the maximum "priming" effect was observed after a 5-to 15-minute incubation depending on the agonist used to induce the aggregation of platelets. The "priming" effect persisted up to 3 hours. MGDF-induced "priming" was detectable at different concentrations of aggregating agents (ADP 0.2 to 0.8 pmolk, EPI: 1 to 24 p m o l k , THR: 0.2 to 1.2 U/mL; data not shown). However, optimal "priming" was observed for the lower concentrations of these agonists (Fig IA) . As shown in Table 1 , MGDF also enhanced the release of ATP induced by ADP, EPI, and THR. MGDF, which by itself did not stimulate the synthesis of TXB2 when added before ADP, EPI, and THR, induced a significant enhancement of TXB2 production (Fig 4) . A "synergic" effect of MGDF on ADP, EPI, and THR was evident when subthreshold concentrations of these agents were added l5 seconds before MGDF (Fig 5) . The minimal effective dose of MGDF required for the "synergic" effect was 20 to 40 ng/mL. All these effects of MGDF were abrogated by 5 minutes of boiling. No effects were observed when platelets were incubated with the vehicle alone instead of MGDF.
RESULTS
Effect of MGDF
Effect of MGDF on platelet aggregation in whole blood. MGDF (1 to 80 ng/mL) by itself did not affect platelet aggregation in whole blood but, as for PRP, "primed" the action of ADP and EPI. As shown in Fig 6, was low in platelets stimulated with MGDF, ADP, EPI, or THR alone as well as in unstimulated platelets. In contrast, when platelets were costimulated with MGDF and ADP, EPI, or THR a higher level of tyrosine phosphorylated p42""'pk was detected.
DISCUSSION
Thrombopoietin is considered a lineage-dominant cytothat regulates the proliferation and maturation of committed cells leading to the production of megakaryocytes and platelets."-x Recently, complementary DNAs for both human and murine thrombopoietin have been cloned and shown to encode a glycoprotein that has selective actions on megakaryocyte proliferation."'." This glycoprotein has a novel two-domain structure with an amino-terminal domain homologous with erythropoietin and a carboxy-terminal domain rich in serine, threonine, and proline residues and conkinef>-8.3fl.>l taining seven potential N-linked glycosylation sites." Several lines of evidence strongly suggest that the c-Mpl protein encoded by the c-mlp proto-oncogene acts as a receptor for thrombopoietin.GR The c-Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to mature platelets?h.'h In c-mpl-deficient mice a decreased number of platelets but not of other hematopoietic cell types was observed.'* The impressive feature of MGDF, the recombinant thrombopoietin, is its ability to increase the number of platelets'". ''.lsso that it may find several potential clinical applications in thrombocytopenic states. " We report herein that MGDF was able to affect the function of mature platelets. We observed that MGDF by itself did not induce platelet aggregation. However, when added before other agonists such as ADP, EPI, and THR, it rendered platelets more sensitive. This "priming" effect of MGDF was dose dependent and it occurred not only in PRP but also in whole-blood platelet aggregation, which better reflects normal physiology. The minimal effective dose was similar to that reported for proliferation of c-mpl-expressing, responsive cell lines3' A "synergic" effect of MGDF on ADP, EPI, and THR was also evident when subthreshold concentrations of these agents were added 15 seconds before MGDF. However, the minimal effective dose of MGDF required for the "synergic" effect was 80 to 160 times higher then the minimal "priming" dose. Similar effects on platelets were previously observed with human stem cell factor which is a hematopoietic growth factor produced by mesenchymal cells acting on c-Kit receptor."
The concept that proliferative cytokines may affect the function of the mature end cells has been demonstrated by studies on the role of granulocyte-macrophage colony-stimulating factor and of granulocyte colony-stimulating factor in "priming" the leukocyte response to activating agents.'s4" The results of present study suggest a modulatory role of thrombopoietin on the function of circulating platelets. This may imply that production of thrombopoietin could be stimulated not only by the reduction of circulating platelets but also by platelet dysfunction.
Recently, it has been suggested that thrombopoietin is released in response to changes in the platelet mass4' and to poorly functioning platelets." In these conditions the humoral factor stimulates megakaryocytes to increase platelet production.J2
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From In our study the priming effect of MGDF was dependent on the time of platelet preincubation as it was already detectable after 30 seconds, reached its maximal after 5 to 30 minutes, and lasted up to 3 hours. This may have clinical implication as treatment with MGDF will involve exposure to this hormone for prolonged period of time. It remains to be determined whether such an increase in platelet responsiveness may be beneficial or detrimental in various clinical thrombocytopenic states.
The intracellular events that occur after thrombopoietin binding to its receptor are poorly understood. Tyrosine phosphorylation of specific intracellular proteins are essential for the action of many hematopoietic growth factors that are known to share common signal transduction ca~cade.~'"~ Recent studies have shown an increase in tyrosine kinase activity on THR-, ADP-, tromboxane A2-or collagen-induced platelet with phosphorylation of several members of Src and Syk families''"s2 and of MAPK." It has been recently shown that platelets express two forms of MAPK, tion, but not P44"'"1'A becomes phosphorylated on serine, threonine, and tyrosine, and functionally activated." In the present study we have evaluated tyrosine phosphorylation of ~4 2 "~ as a marker of increased tyrosine kinase activity. The results obtained indicate that MGDF enhanced phosphorylation of ~4 2 " ' "~~ promoted by ADP, EPI, and THR.
It has been suggested that in platelet p42"""' could modulate cytoscheletal protein functions in secretion and adhesion.'" Another potential substrate for p42"'1'pk in platelets is cytosolic phospholipase A2.s3,s4 It has been shown that MAPK belongs to the platelet signal transduction pathway involved in the activation of phospholipase A2 and in the mobilization of arachidonic acid." Miyakawa et al" reported that MGDF induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Our results indicating that MGDF "primes" the phosphorylation of p 4 2 ' I h further support the contention of Miyakawa et a15" that the ligand binding to c-mpl activates signal transduction in human platelets. It is possible that Jak2, Shc. and p42""" may be involved in the increase in platelet sensitivity to physiologic agonists induced by MGDF.
In conclusion, these results suggest that thrombopoietin has pleiotropic effects, because, besides acting as an hematopoietic growth factor. it potentiates platelet activation. There-" l g 
